Kronos Bio Inc expected to post a loss of 28 cents a share - Earnings Preview

* Kronos Bio Inc is expected to show a rise in quarterly revenue when it reports results on November 11 (estimated) for the period ending September 30 2024

* The San Mateo California-based company is expected to report a 129.0% increase in revenue to $2.1 million from $917 thousand a year ago, according to the mean estimate from 4 analysts, based on LSEG data.

* ​LSEG's mean analyst estimate for Kronos Bio Inc is for a loss of 28 cents per share.

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The mean earnings estimate of analysts was unchanged in the last three months. ​

* Wall Street's median 12-month price target for Kronos Bio Inc is $4.13​, above​ its last closing price of $0.90. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT ESTIMATE MET, SE %

E® MISSED

Jun. 30 2024 -0.33 -0.34 -0.27 Beat 20

Mar. 31 2024 -0.42 -0.42 -0.29 Beat 31.4

Dec. 31 2023 -0.53 -0.52 -0.34 Beat 35.2​

Sep. 30 2023 -0.45 -0.51 -0.54 Missed -5.4

​​Jun. -0.43 -0.46 -0.52 Missed -13

30 2023

Mar. 31 2023 -0.27 -0.44 -0.46 Missed -3.4​

Dec. 31 2022 -0.48 -0.59 -0.56 Beat 4.4

Sep. 30 2022 -0.65 -0.65 -0.57 Beat 12.6

This summary was machine generated November 8 at 15:49 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)